Work

Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC)

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx371.017

Authors: T. Zhang, M. Harrison, P. O'Donnell, A. Alva, N. Hahn, L.J. Appleman, J. Cetnar, J. Burke, M. Fleming, M. Milowsky, A. Mortazavi, N. Shore, E.V. Schmidt, C. Kresja, T. Chen, B. Bitman, R. Izumi, A. Hamdy, D.J. George

Institutions: Duke Medical Center, Duke Cancer Institute, University of Chicago Medical Center, University of Michigan, Michigan Medicine, Johns Hopkins University, UPMC Hillman Cancer Center, Oregon Health & Science University, Rocky Mountain Cancer Centers, Virginia Oncology Associates, UNC Lineberger Comprehensive Cancer Center, The Ohio State University, Carolina Urologic Research Center, Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, AstraZeneca, Exelixis, Astellas Pharma, Genentech

OpenAlex ID: W2762020624

FWCI: 0.56

Cites:

Cited by: 2

Related to: 10